Company
Nalu Medical
Last checked: Nov 21, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
1
510(k), De Novo and PMA
Device trials
3
As lead sponsor, any status
Adverse event reports
612
Received Nov 1, 2025 to Nov 21, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$127M
2 Form D offerings, 2015 to 2023
Equity
$127M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $115M raised of $115M sought, first sale Dec 21, 2023, 29 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Dec 21, 2023 | Equity | $115M | $115M | 29 | Rule 506(b) | Form D/A ↗Oct 9, 20242 amendments |
1 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- Nalu Medical, Inc.
- Headquarters
- Carlsbad, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1647424 ↗
Executives, directors and promoters
As listed on the latest Form D.
15 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.
No 5%+ shareholder filings, SBIR grants or venture investors found under the name Nalu Medical.
Latest FDA decisions
K191435 · Decided Sep 6, 2019 · 99 days after receipt
Device type: Stimulator, Peripheral Nerve, Implanted (Pain Relief) (GZF) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic PainPivotal-lookingActive, not recruiting
NCT05287373 · 131 participants · Start Feb 23, 2022 · Primary completion Dec 11, 2023
Device: Nalu Neurostimulation System for PNS · For: Peripheral Neuralgia; Chronic Pain
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Burbank, California · 13 sites in all
2 more trials with a free account
Reports received
612
Received Nov 1, 2025 to Nov 21, 2026. Includes 1 of another or unstated type.
Malfunction reports
121
20% of reports
Injury reports
487
80% of reports
Death reports
3
0.5% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 30 | 0 | 0 |
| Jan 24 | 1 | 41 | 0 | 0 |
| Feb 24 | 0 | 27 | 0 | 0 |
| Mar 24 | 1 | 38 | 0 | 0 |
| Apr 24 | 0 | 43 | 0 | 0 |
| May 24 | 0 | 54 | 0 | 0 |
| Jun 24 | 0 | 40 | 0 | 0 |
| Jul 24 | 0 | 38 | 0 | 0 |
| Aug 24 | 0 | 36 | 0 | 0 |
| Sep 24 | 0 | 43 | 0 | 0 |
| Oct 24 | 0 | 44 | 0 | 0 |
| Nov 24 | 0 | 29 | 0 | 0 |
| Dec 24 | 0 | 36 | 0 | 0 |
| Jan 25 | 0 | 42 | 0 | 0 |
| Feb 25 | 1 | 24 | 0 | 0 |
| Mar 25 | 0 | 46 | 0 | 0 |
| Apr 25 | 0 | 29 | 0 | 1 |
| May 25 | 0 | 28 | 0 | 0 |
| Jun 25 | 0 | 20 | 0 | 0 |
| Jul 25 | 0 | 36 | 0 | 0 |
| Aug 25 | 0 | 36 | 0 | 0 |
| Sep 25 | 0 | 19 | 0 | 0 |
| Oct 25 | 0 | 24 | 0 | 0 |
| Nov 25 | 0 | 16 | 0 | 0 |
| Dec 25 | 0 | 20 | 0 | 0 |
| Jan 26 | 0 | 12 | 0 | 0 |
| Feb 26 | 0 | 29 | 0 | 0 |
| Mar 26 | 1 | 32 | 0 | 0 |
| Apr 26 | 1 | 12 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 1 | 8 | 0 | 0 |
| Jul 26 | 1 | 9 | 0 | 0 |
| Aug 26 | 1 | 8 | 0 | 1 |
| Sep 26 | 43 | 44 | 0 | 0 |
| Oct 26 | 73 | 297 | 3 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
The full in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2257-2024 · Started Jun 3, 2024 · Posted by FDA Jul 3, 2024
Reason given: Neurostimulation Systems have a manufacturing non-conformance that may reduce the efficiency of the radiofrequency signals between the Implantable Pulse Generator (IPG) and the Therapy Disc, causing the IPG to be non-functional, which causes the device to be non-functional so it will no longer inhibit the transmission...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Stimulator, Peripheral Nerve, Implanted (Pain Relief) (GZF)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.